To view or add a comment, sign in GLP1, Wegovy, has recently been FDA-approved for MASH patients with moderate-to-advanced fibrosis hot on the heels of last years approval of first-mover, Rezdifrra
law, compounding may occur through patient-specific prescriptions (503A pharmacies) or by FDA-registered outsourcing facilities (503B), and is generally permitted only when there is a legitimate clinical need or drug shortage
It's going to be a little different than what the hyperscalers are doing, just given the nature of their balance sheets
The previous interactions contribute to the activation of the peripheral immune system and primes CNS microglia, creating a neuroinflammatory environment that aggravate behavioral deficits (Manda et al., 2012
We will evaluate the BPC 157 half life impacts, and offer suggestions for optimal dosage timing to enhance efficiency